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Abstract 
The nonalcoholic steatohepatitis is the leading cause of hepatic morbidity and 
mortality, the patients being at very high risk of developing cirrhosis, liver failure and 
hepatocellular carcinoma. Its growing incidence and prevalence in patients with diabetes 
mellitus and metabolic syndrome indicates that these entities have at least one common 
pathogenic mechanism, where the main factors are visceral obesity and insulin resistance. 
Purpose: The purpose of this study was to explore the prevalence of nonalcoholic 
steatohepatitis in a group of patients with type 2 DM from the Timis County, as well as 
NASH relationships with other cardiovascular risk factors, such as obesity, dyslipidemia and 
arterial hypertension.  
Material and method:  The study included 310 patients with type 2 DM, 123 men (39.7%) 
and 187 women (60.3%) with mean age 59.6 ± 8.1 (39-79) years, treated within the 
Antidiabetes Center Timisoara between March-December 2012.  
Results and discussions: The nonalcoholic steatohepatitis was diagnosed in 208 patients 
(71.5%), 90 men (78.9%) and 118 women (66.6%), its prevalence being higher in males. 
Analyzing the metabolic syndrome components, we found that all examined parameters were 
statistically significantly higher in patients with nonalcoholic steatohepatitis, showing an 
extremely high cardiovascular risk in this category of patients.  
Conclusions: The therapeutic strategy in nonalcoholic steatohepatitis involves the decrease of 
visceral fat and the improvement of insulin resistance. 
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Introduction 
We are witnessing an epidemic of metabolic diseases, as demonstrated by the 
alarming increase in the number of cases with diabetes mellitus (DM).  
At the end of 2012, over 371 million people with DM were recorded, of which 50% 
undiagnosed. In Europe, their number reached 55 million, of which 38.6% undiagnosed.  
 Type 2 DM is accompanied by a two-three times increase of the risk of cardiovascular 
disease (CVD), which is considered equivalent to a CVD. In fact, 50% of deaths in patients 
with DM are due to CVD and only in 15% of cases they are caused by its direct 
complications. 
This is due to a presence of several cardiometabolic risk factors (CMR), such as: ▪ 
disorders of lipid metabolism, manifested by the increase of the small and dense particles of 
LDLc, serum TG, Apo B, and the decrease of HDLc, ▪ hypercoagulability, ▪ arterial 
hypertension (AHT), ▪ insulin resistance (IR) and ▪ inflammation. 
The association with the nonalcoholic steatohepatitis (NASH) enhances this risk by 
increasing the release of proinflammatory cytokines and decreasing the adiponectin secretion.  
 NASH covers a wide spectrum of liver damage, from isolated macrovesicular 
steatosis to steatohepatitis associated by macrovesicular steatosis, lobular and perisinusiodal 
necroinflammmatory lesions, hepatocitary inflammation and Mallory bodies, to advanced 
fibrosis and cirrhosis, in the absence of a relevant alcohol consumption (<20 g/day). NASH is 
the leading cause of hepatic morbidity and mortality, the patients with NASH being in a very 
high risk to develop cirrhosis, liver failure and hepatocellular carcinoma (Brunt, 1999, 
Chitturi, 2001). 
 It is estimated that the prevalence of NASH in developed countries in Western Europe 
and the USA covers 20 to 30% of the population. 
 Although the exact cause is not fully known, the incidence and prevalence of NASH 
in patients with DM and metabolic syndrome (MS), shows that these entities have at least one 
common pathogenic mechanism, where visceral obesity and IR play the main role (Hsiao, 
2007, Marchesini, 2002). 
 Type 2 DM is present in 21-45% of patients with NASH, and NASH is present in 49-
86% of patients with type 2 DM. After Bugianesi E et al, NASH is associated with obesity in 
60-95% of cases; with type 2 DM in 28-55% of cases and with dyslipidemia in 27-92% of 
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cases (Bugianesi, 2005). NASH is considered a hepatic manifestation of MS, reflected by the 
fact that 90% of patients with NASH meet more than one criterion for the diagnosis of MS, 
and 33% have three or more diagnostic criteria (Amarapurkar, 2004). Also, each additional 
criterion of MS enhances exponentially the risk of NASH. 
 Hyperinsulinemia, caused by the elevated insulin secretion by the pancreatic beta cells 
and reduced insulin degradation by the liver, is a compensatory phenomenon of IR. 
Hyperinsulinemia leads to increased fat mass and lipogenesis, being associated with 
increased concentration of free fatty acids (FFA) (Marceau, 1999, Marchesini, 2003). 
 Adipocytes represent an active endocrine organ that produces and secretes a number 
of cytokines (adipokines) that help regulate the metabolic processes. The most important 
proinflammatory cytokines secreted by adipocytes are tumor necrosis factor (TNF-alpha), 
resistin, leptin and plasminogen activator inhibitor (PAI), which contribute to the alterations 
leading to IR (Bray, 1992).  
The concentration of adiponectin, produced exclusively by adipocytes, is low in 
patients with IR, type 2 DM and NASH. It is proven that adiponectin reduces IR by 
increasing FFA oxidation, decreasing triglycerides (TG) in the liver and muscle, and by 
inhibiting the liver glucose production. 
 NASH results from the TG accumulation in hepatocytes. FFA derived from food 
intake and released from the fat stores, become esterified into TG with the help of 
diacylglycerol acyltransferase enzyme (DGAT), the enzyme that catalyzes the final step of 
TG synthesis in the liver. Finally, TG are released from the liver as VLDL. 
 Leptin may play the role of an antisteatosis hormone, preventing the accumulation of 
FFA and fats in non-adipose tissues. In addition, leptin appears to be essential for the 
development of hepatic fibrosis, in response to chronic liver alterations induced by the 
transforming growth factor beta 1. 
The oxidative stress is recognized as a mechanism responsible for the progression of 
liver damage. Oxidative stress includes oxygen free radicals and lipid peroxidation (Cortez-
Pinto, 2001). The mitochondrial β-oxidation processes of FFA are deeply altered in patients 
with NASH, the consequence of this imbalance being the formation of oxygen free radicals, 
which are responsible for the increased synthesis of TNF-alpha, inducing lesions of necrosis, 
inflammation and hepatocyte fibrosis (Munteanu, 2008, Pessayre, 2001).  
 The increased TNF-alpha liver expression in NASH represents the connection 
between the development of IR and the hepatic steatosis. TNF-alpha holds a significant 
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mechanism in the development of peripheral IR in patients with obesity and type 2 DM 
(Koruk, 2004, Yadav, 2002). 
Main Text 
Objectives and aims 
Starting from these premises, the principal aim of our study was to explore the 
prevalence of nonalcoholic steatohepatitis in a group of patients with type 2 DM treated 
within the Center of Diabetes from Timisoara, as well as NASH relationships with other 
cardiovascular risk factors (CVR): obesity, dyslipidemia, hypertension (AHT).  
Materials and methods 
 The study included 310 patients with type 2 DM, 123 men (39.7%) and 187 women 
(60.3%) with mean age 59.6 ± 8.1 (39-79) years, treated within the Antidiabetes Center 
Timisoara between March-December 2012.         
Data on alcohol consumption or use of medicines that might cause hepatic lesions 
were obtained by direct questioning of the patient, as well as confirmation of their family 
members.  
            Following parameters were assessed; sex, age, waist circumference (WC) as well as 
data concerning AHT presence. Body mass index (BMI) was calculated using the formula: 
body weight (kg) /height (m2); the patients with BMI >30 kg/m2 were considered obese.    
Total cholesterol (TC), serum triglycerides (TG) and liver transaminases: ASAT and 
ALAT, viral markers, anti-hepatitis B antigen and anti-hepatitis C antibodies were measured 
in all patients. 
Glycemic control was assessed by measuring HbA1c (by the latex- 
imunoagglutination inhibition assay, with the DCA analyzer and with the result displayed 
within 6-8 minutes). 
The hepatic steatosis was measured by abdominal ultrasonography and classified as 
mild, moderate and severe. The fibrosis degree was established using the FibroScan, a device 
measuring the elasticity of the liver tissue by a mechanical wave that propagates through the 
liver, its speed being monitored by an ultrasound beam. This method has the advantage of 
being completely non-invasive, objective (minimum interobserver variability), reproducible 
and fast.  
The result of the examination is actually the average of 10 successive assays validated 
by the device. On such basis, the degree of fibrosis is assessed from 0 to 4. Normal values 
must fall between 5.5 ±1.6 kPa. Age does not influence the values, but the values are higher 
in men (5.8 ± 1.5 kPa) than in women (5.2 ± 1.6 kPa). In obese individuals, the normal values 
are 6.3 ± 1.9 kPa for men and 5.4 ± 1,5 kPa for women. 
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The approximate correspondence between the degree of hepatic fibrosis and the 
results of FibroScan is as follows: ● F1< 7 kPa – can be mixed up with normal liver, ● 
F2>7.1 kPa, ●F3 > 9.5 kPa, ● F4 (cirrhosis) > 12,5 kPa. The predictive value is about 80% 
for fibrosis ≥ F2, 90% for fibrosis ≥ F3 and 95-97% for fibrosis = F4. In principle, the result 
is correct in approximately 95% of the tested patients, and the correlation between the 
FibroScan outcome and liver biopsy is about 90%. 
 The characteristics and biological variables were expressed by mean value ± standard 
deviation (SD).  
Results  
 Of the 310 patients included in the study, hepatitis B virus was detected in 10 patients 
(3.2%); hepatitis C virus in 9 patients (2.9%) and one of the patients was infected with both 
viruses. After we excluded them, we analyzed the study group to ascertain NASH prevalence, 
as well as its relationship with other CVR factors. 
Based on abdominal ultrasonography, the 291 investigated patients with type 2 DM 
were classified as follows: 83 patients (28.5%) without steatosis (S0), 61 patients (21%) with 
minimal or mild steatosis (S1), 79 patients (27.1 %) with moderate steatosis (S2) and 68 
patients (23.4%) with severe steatosis. (S3), (Figure 1). 
 
 
28,5%
27,1%
21%
23,4%
 
Figure 1. Distribution of the group after the degree of steatosis 
 
 NASH prevalence in the study group was 71.5%, being higher in men in women: 
78.9%, respectively 66.6% (Figure 2).  
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Figure 2. NASH prevalence, by gender 
 
The main characteristics of the two patient groups (with NASH and without NASH) 
are shown in Table 1. 
Table 1. Comparison between the two groups of patients, with and without NASH 
Parameter with NASH without NASH  
No. (%) 208 (71.5%) 83 (28.5%)  
 Average ± SD Average ± SD p 
Age (years) 60.3 ± 8.9 58.9 ± 6.8 0.19 (NS) 
BMI (kg/m2) 31.2 ± 5.4 28,4 ± 5 <0.0001 (ES) 
WC (cm) men 109 ± 16.6 101.4 ± 15.8 <0.0001 (ES) 
WC (cm) women 94.3 ± 11.5 84.5  ± 9.6 <0.0001 (ES) 
DM (years) 9 ± 5.3  7 ± 4.6  0.0028 (FS) 
HbA1c (%) 7.8 ± 1.8 7.3 ± 1.6 0.028 (S) 
TC (mg/dl) 201.1  ± 41.2  178.6 ± 28.8 <0.0001 (ES) 
TG (mg/dl) 209.3 ± 113.5  161.9 ± 75.9  0.0005 (ES) 
HDLc (mg/dl) 39.4 ± 1.8 44.4 ± 2.1 <0.0001 (ES) 
LDLc (mg/dl) 118 ± 39 100 ± 36 <0.0001 (ES) 
ASAT (U/L) 30.8 ± 14.2  29.4 ± 25.8  0.555 (NS) 
ALAT (U/L) 39.3 ± 26.9  31.9 ± 18.3  0.022 (S) 
AHT no. (%) * 148 (71.1%) 38 (45.8%) 0.083 (NS)  
SBP (mmHg) 159.8 ± 44.1 136.6 ± 32.8 <0.0001 (ES) 
* Values are expressed as number and percentage 
 
Statistically significant differences were noticed in all examined parameters, except 
age and ASAT value (Table 1).  
 Using the FibroScan we measured the degree of fibrosis in the patients included in the 
study, and they were classified as follows: 86 patients (29.6%) without fibrosis (F0); 118 
patients (40.5%) with minimal or mild fibrosis (F1); 44 patients (15.1%) with moderate 
fibrosis (F2); 25 patients (8.6%) with severe fibrosis (F3) and 18 patients (6.2%) with 
cirrhosis (F4) (Figure 3).  
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Figure 3.  Distribution of study group, according to the degrees of fibrosis obtained with the FibroScan 
 
 Although there are slightly elevated liver transaminase levels, they may be normal 
even in the presence of severe liver damage. Note that elevated ALAT and ASAT were 
detected only in 39 patients (18.7%) of the ones with significant steatosis tested by abdominal 
ultrasound. 
We analyzed the relationship between the mean values of ASAT and ALAT, and the 
degrees of steatosis and fibrosis within the study group (Table 2). 
Table 2. Mean ASAT and ALAT values, depending on the degrees of steatosis and fibrosis at the study group. 
Parameter Steatosis Fibrosis 
 0 1 2 3 0 1 2 3 4 
ASAT (U/L) 24.5 ± 
21.4 
29.4 
± 
24.2 
32.6 
± 
26.8 
33.9 
± 
28.4 
24.6 
± 
18.9 
27.6 ± 
20.8 
30.2 ± 
21.3 
34.3 ± 
22.6 
33.8 
± 
22.4 
 
ALAT (U/L) 34.9 ± 
18.3 
35 
± 
21.3 
35.7 
± 
24.1 
36.8 
±  
26.4 
32.7 
± 
19.7 
34.8 ± 
20.8 
35 
± 
21.1 
36.8 ± 
23.4 
38.9 
± 
24.6 
 
We noticed that ASAT and ALAT values increase directly proportional to the 
increase of the degree of hepatic steatosis and fibrosis, but without statistically significant 
differences.  
Analyzing the weight status of the patients with NASH, we found that 192 patients 
(92.3%) were overweight or obese (Figure 4). 
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Figure 4. Weight status of the patients with NASH 
 
AHT was found in 149 patients (71.6%) with NASH, with a statistically significant 
difference between the mean value of SAT in patients with NASH, as compared to those 
without NASH: 159.8 mmHg versus 136.6 mmHg (<0.0001 (ES). In patients with type 2 DM 
and NASH, the prevalence of dyslipidemia was 80.3%.  
 Given that all patients with NASH were diabetic and 92.3% of them were overweight 
or obese, the MS criteria were met in all 208 patients with NASH: 54 patients (26%) met 3 
diagnostic criteria of MS; 84 patients (40.4%) 4 criteria and 70 patients (33.6%) 5 diagnosis 
criteria (Figure 5). 
26 %
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Figure 5. MS, depending on the number of diagnostic criteria in the study group 
 
The main cause of death in patients with type 2 DM is CVD. The ADVANCE risk 
engine is a CVR calculator developed for people with DM. It estimates the probability of a 
major cardiovascular event in 4 years, including CV death, non-fatal myocardial infarction 
and non-fatal cerebral vascular accident (stroke).  
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To assess CVR, the ADVANCE risk engine records the following 10 factors: age at 
diagnosis, duration of DM, sex, arterial pressure (blood pressure), the presence of diabetic 
retinopathy and arterial fibrillation, urine albumin/creatinine ratio, non-HDLc, the existence 
of antihypertensive treatment and the HbA1c value.  
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Figure 6. CVR in patients with type 2 DM and NASH, versus those without NASH, based on the ADVANCE risk 
engine 
 
Based on the ADVANCE risk engine, we ascertained within the study group that the 
CVR in patients with type 2 DM and NASH is 2.5 higher than in those with type 2 DM 
without NASH: 24%, versus 9.8%. (Figure 6).  
Discussions 
NASH is nowadays considered as the hepatic manifestation of MS, caused by the 
same etiopathogenic mechanisms, namely IR, abdominal (visceral) obesity, high calorie/high 
fat foods and a sedentary lifestyle. NASH is considered to be an early manifestation form of 
IR and is predictive for the subsequent development of the other MS component parts.  
Recent studies have shown that NASH is now the most important chronic liver 
disease leading to cirrhosis, hepatocellular carcinoma, and finally death. It seems that 20% of 
the patients with NASH develop cirrhosis, and 30-40% of those with cirrhosis require a liver 
transplant or die due to very severe complications (Pascale, 2010).  
Chronic hyperinsulinemia causes the accumulation of TG in hepatocytes and, by 
definition, the accumulation of TG in hepatocytes is needed for the development of NASH. 
The peripheral IR and the compensatory hyperinsulinemia lead to accumulation of fat 
in the liver. Normally, the insulin levels increase postprandial, stimulating glucose uptake in 
muscle and fat. The increase of postprandial insulinemia stops the release of FFA from the 
adipocytes (fat cells) and reduces the glucose produced by hepatocytes (Paloma, 2009). 
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Dyslipidemia, especially hypertriglyceridemia, stimulates the increase of VLDL-c and 
the decrease of HDL-c, accelerating the processes of atherosclerosis in patients with type 2 
DM. 
Several studies showed that NASH is 2-3 times more frequent in obese patients and in 
patients with type 2 DM, being present in almost all cases where these two diseases were 
associated. 
Some recent data indicate a significant rise of NASH prevalence in children:   from 
2.6% a decade ago, to 5% at present in children with a normal weight; to 38% in the ones 
with obesity, and to 48 % in those with DM.  
Ong et al. showed that the most common causes of death recorded in patients with 
NASH are due to cardiovascular and neoplastic diseases. For this reason, NASH is currently 
considered as the hepatic manifestation of MS, being an independent predictor of CV 
morbidity and mortality (Ong, 2008). Studies like Hoorn Study, the Framingham Heart Study 
and Valpolicella Heart Diabetes Study showed that there was a strong association between 
elevated serum transaminases and increased CVR. 
Studies like the Hoorn Study, the Framingham Heart Study and Valpolicella Heart 
Diabetes Study showed the existence of a strong association between elevated serum 
transaminases and increased CVR (Goessling, 2008, Schindhelm, 2007, Targher, 2006).  
Nowadays, NASH prevalence in patients with DM is estimated between 35-75%, 
even to 100% in patients with DM and obesity.  NASH prevalence recorded in our study 
group reached 71.5%, being higher in men than in women.  
At the FibroScan examination, almost 30% of the patients were diagnosed with 
fibrotic lesions, and 18 patients (6.2%) even showed cirrhotic lesions (F4 > 12.5 kPa).  
MS elements were present in almost all patients included in the study: all had type 2 
DM; 92.3% of them were overweight or obese; 71.6% were hypertensive and 80.3% were 
diagnosed with dyslipidemia.  
Gianfranco Pagano et al. aimed to ascertain the presence of MS components in 
patients with NASH, as well as the correlation between liver lesion and peripheral 
hyperinsulinemia. Compared with the control group, the group with NASH recorded a higher 
value of insulin secretion and lower insulin sensitivity (Pagano, 2002). In addition, 9 patients 
(47%) showed at least 2 MS diagnostic criteria, according to the European Group for the 
Study of Insulin Resistance (EGIR) and World Health Organization (WHO) (Alberti, 1998, 
Balkau, 1999). 
European Scientific Journal    April 2013 edition vol.9, No.12    ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
109 
 
 A study conducted in Taiwan included 16,486 patients and focused on establishing 
the correlation between the gravity of hepatic lesions and the presence of IR and MS. The 
patients were divided into 3 groups: without hepatic steatosis; with moderate steatosis and 
with severe steatosis. Prevalence of obesity, AHT, glycoregulation disorders and 
hypertriglyceridemia were statistically significant higher in the group of patients with severe 
steatosis. Also, BMI ≥30 kg/m2, seems to be the most important factor in the progression 
from moderate to severe hepatic steatosis, in both sexes. The study shows that patients with 
severe hepatic lesions have an increased CVR and that they must be examined periodically to 
detect metabolic disorders. NASH is recognized as the most common liver disease in the 
U.S., with a prevalence of 10-24%; similar data were recorded in Europe and Japan. Many 
studies showed the direct correlation between NASH and MS components, as WC, serum TG 
and HDLc. Peripheral IR and compensatory hyperinsulinemia interfere with homeostatic 
mechanisms that lead to fat accumulation in the liver.  
 In conclusion, the central role of IR in the pathogenesis of NASH suggests that direct 
intervention in improving insulin sensitivity may be beneficial in slowing the progression or 
the reversal of this disease.  
Conclusion 
To prevent CVR, the therapeutic strategy in NASH has two goals: to reduce visceral fat 
and to improve IR. The only effective method is the lifestyle change (to reduce excess weight 
by 5-10% with a low fat diet and an appropriate and individualized physical exercise). 
In the case of persons with DM, achieving and maintaining optimal glycemic control is 
the best way to prevent NASH. 
 
References: 
Alberti KGMM, Zimmet PZ for the WHO consultation. Definition, diagnosis and 
classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of 
diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.  
Amarapurkar DN, Patel ND. Prevalence of metabolic syndrome in non-diabetic and non-
cirrhotic patients with non-alcoholic steatohepatitis. Trop Gastroenterol 2004; 25: 125-129.  
Balkau B, Charles MA, for the European Group for the Study of Insulin Resistance (EGIR). 
Comment of the provisional report from the WHO consultation. Diabet Med 1999; 16: 442-
443. 
Bray GA - Pathophysiology of obesity. Am J Clin Nutr, 1992; 55 (Suppl):488S-494S.  
European Scientific Journal    April 2013 edition vol.9, No.12    ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
110 
 
Brunt EM si colab. - Non-alcoholic steatohepatitis: a proposal for grading and staging the 
histological lesions. Am J Gastroenterol, 1999; 94:2467-2474. 
Bugianesi E, McCullough A, Marchesini G. Insulin resistance: A metabolic pathway to 
chronic liver disease. Hepatology 2005; 42: 987-1000. 
Chitturi S, Farrell GC - Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver 
Disease, 2001; 21:27-41.  
Cortez-Pinto H - Oxidativ stess in alcoholic and nonalcoholic fatty liver disease. 
Steatohepatitis (NASH and ASH), Falk Symposium. Dordrecht: Kluwer Academic 
Publishers, 2001; 121: 54-61. 
Cortez-Pinto H si colab. - Hepatic stellate cell activation occurs in nonalcoholic 
steatohepatitis. Hepato-Gastroenterol, 2001; 4B: 87-90.  
Goessling W, Massaro JM, Vasan RS et al. Aminotransferase levels and 20-year risk of 
metabolic syndrome, diabetes and cardiovascular disease. Gastroenterology 2008;: 135 (6): 
1935-1944.  
Halfon et al, FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin 
Biol 2008; 32: 22-38.  
Hsiao PJ, Kuo KK, Shin SJ et al. Significant Correlations Between Severe Fatty Liver and 
Risk Factors for Metabolic Syndrome. J Gastroenterol Hepatol 2007; 22(12): 2118-2123.   
Koruk M si colab. - Oxidativ stress and enzymatic antioxidant status in patients with 
nonalcoholic steatohepatitis. Ann Clin Lab Science, 2004; 34:57-62.  
Marceau P, Biron S, Hould F et al. Liver pathology and the metabolic syndrome X in severe 
obesity. J Clin Endocrinol Metab 1999; 84: 1513-1517.  
Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the 
metabolic syndrome. Hepatology 2003; 37: 917-923.  
Marchesini G, Forlani G - NASH: from liver diseases to metabolic disorders and back to 
clinical hepatology. Hepatol, 2002; 35:497-499.  
Munteanu et al, Noninvasive biomarkers for the screening of fibrosis, steatosis and 
steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax Experience. J 
Gastrointestin Liver Dis. 2008; 17: 187-191.  
Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-
alcoholic fatty liver disease. J Hepatol 2008; 49 (4): 608-612.  
Pagano G, Pacini G, Musso G et al. Nonalcoholic Steatohepatitis, Insulin Resistance, and 
Metabolic Syndrome: Further Evidence for an Etiologic Association. Hepatology 2002; 367-
372.   
European Scientific Journal    April 2013 edition vol.9, No.12    ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
111 
 
Paloma Almeda-Valdes, Daniela Cuevas-Ramos, Carlos Alberto Aguilar-Salinas. Metabolic 
syndrome and non-alcoholic fatty liver disease. Annals of Hepatology 2009; 8(1): 
Supplement: S18-S24.  
Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and 
future directions. J Gastrointestin Liver Dis 2010; 19:415.  
Pessayre D, Berson A, Fromenty B - Mitochondria in steatohepatitis. Semin in Liver Disease, 
2001; 21:57-69.  
Poynard et al, Methodological aspects for the interpretation of liver fibrosis non-invasive 
biomarkers: a 2008 update. Gastroenterol Clin Biol 2008; 32: 8-21.  
Schindhelm RK, Dekker JM, Nijpels G et al. Alanine aminotranferase levels predicts 
coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis 2007; 
191: 391-396.  
Targher G, Bertolini L, Tessari R et al. The International Diabetes Federation definition of 
metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic 
patients. The Valpolicella Heart Diabetes Study. Diabet Med 2006; 23 (11): 1270-1271.   
Yadav D si colab. - Serum and liver micronutrient antioxidants and serum oxidativ stress in 
patients with chronic hepatitis C. Am J Gastroenterol, 2002; 97: 2634-2649. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
